Clinical Trial Update: STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on the STORM regimen (temsirolimus, rituximab, and DHAP) for relapsed or refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• DHAP regimen
• Rituximab (rituximab)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Mathias Witzens-Harig | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: UNKNOWN